With over 20 years of experience working with both private and listed business, Stephen has provided key financial and strategic advice since inception. Prior to joining 4D pharma plc, Stephen was Group Finance Director of Aquarius Equity Partners, a European healthcare fund. Stephen’s role was key in not only the development of the funds, but also the financial stability of the group. At Aquarius, Stephen also played a key role in the development of the portfolio, working with management teams across companies such Nanoco Technologies, Tissue Regenix and Auralis, as well playing a more formal role as interim FD at Brabant Pharma. After qualifying as a Chartered Accountant with Tenon (now RSM), and working as Group FD for a local engineering company, Stephen founded an accountancy practice, Summ.it Assist LLP, which delivers outsourced tailor-made solutions covering financial, HR and IT solutions to SMEs and, since inception, has grown to over 30 staff across offices in Manchester and Mauritius. During this time Stephen has also acted as non-executive director for various SMEs and spent 18 months as interim FD for Touchstar Technologies during the successful reverse takeover of that business by Belgravium Technologies plc.

Christophe graduated in industrial pharmacy, and he started his industrial career as plant manager for Lallemand Bacteria Division, then occupied various positions in R&D and Marketing in B2B of Pharmaceuticals Ingredients. When presented with the challenge of producing Blautix™ he succeeded where others had previously failed and immediately understood the potential of this microorganism. Now, he is in charge of the pharmaceutical industrial development of all the 4D pipeline with the responsibility of all manufacturing sites.

Laurie is General Counsel and Company Secretary of 4D pharma plc. In his role, he works closely with the Board and senior team, and supports all those within 4D in legal and regulatory compliance. He also co-ordinates the Group's external legal requirements. Prior to joining 4D pharma, Laurie was a corporate lawyer in private practice for over 20 years, holding senior positions with Addleshaw Goddard LLP and Schofield Sweeney LLP. He specialised in mergers and acquisitions and private and public fundraisings (advising corporates, funders and managers alike), and advised both private and quoted businesses generally on all aspects of corporate law. His clients were predominantly technology focussed and included Aquarius Equity Partners, Nanoco Technologies plc, Sanderson Group plc and C4X Discovery Holdings plc. He was also previously external counsel to 4D pharma, and advised it in relation to its IPO and initial fundraisings. He remains a qualified solicitor.

Imke Mulder is the Research Director at 4D pharma Research Ltd in Aberdeen, Scotland, where she leads a multidisciplinary research group of 30 scientists. After completing her BSc and MSc in Biology at Wageningen University in the Netherlands, she moved to Aberdeen in 2001 to pursue her PhD studies at the Department of Zoology, working on the effects of dietary components on the gut immune system. Imke then carried out 8 years of post-doctoral work as a Research Fellow in the Gut Immunology Group at the Rowett Institute of Nutrition and Health (RINH) in Aberdeen. This work primarily focussed on interactions between the gut microbiota and the host immune system in different model organisms. Specific projects investigated how microbial composition and diversity influences early-life development of the mucosal immune system, and the cell-specific signalling pathways and effector molecules involved in driving health-promoting interactions of the gut microbiota. Imke moved to 4D pharma Research Ltd in 2014 where she leads the development of the MicroRx platform for the discovery of new live biotherapeutics.

Antonio was the Chief Executive Officer at Instituto Biomar from 2002, leading a group of fermentation specialist and research scientists in microbiology and natural products chemistry. He received his PhD at Houston’s M.D. Anderson Cancer Centre, conducting post-doctoral work in the Departments of Cell Biology and Molecular Pathology from the same institution. After this, Antonio worked in the Departments of Tumour Immunology, at the Dana-Farber Cancer Institute and then Surgical Research at the Children's Hospital, both associated with Harvard Medical School in Boston. He moved back to Spain in 2001, and worked at the research unit in Hospital de Leon from 2001 to 2002, when he joined Instituto Biomar. After the acquisition of Biomar´s production unit by 4D pharma in April 2016, Antonio took up the position of director at 4D pharma Leon.

Eileen has a BSc in Plant Science and aPhD in Plant Biotechnology from University College Cork (UCC). She has worked as a post-doctoral researcher and as a manager on a range of projects both at national and EU level spanning plant and human health. In 2013, Eileen was project manager of ELDERMET, a nationally funded project that established diet-microbiota health interactions in over 500 elderly people. Following this post, she managed the Centre for Gerontology & Rehabilitation, UC,C where she was involved in initiatives focused on the elderly which also supported the European Innovation Partnership on Active and Healthy Ageing. She joined the APC Microbiome Institute (APC) in 2014 as EU Grants Manager where she engaged with stakeholders, built collaborations, inputted into draft work programmes and policy documents, and identified opportunities for microbiome research at national, EU and international level. She has over a decade of experience of working with industry partners in the capacity of research project manager and as a consultant. Eileen is very active in communicating science and creating an awareness through education and public engagement. She is also a member of the APC Microbiome Institute faculty. As Site Manager of 4D pharma Cork Limited, Eileen is responsible for the day-to-day running of the site including: management of clinical trials, administration, HR and liaising with other 4D sites and central management.

BACK TO TOP